跳至主要内容
临床试验/NCT00286013
NCT00286013已完成2 期

Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

University Hospital, Ghent4 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2004年5月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
24
试验地点
4
主要终点
Feasibility

研究概览

简要总结

The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease
  • •WHO performance status of 0 or 1
  • •Complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed
  • •Maximum delay after surgery: 8 weeks
  • •No previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ
  • •Adequate bon marrow reserve
  • •No previous chemotherapy or radiotherapy
  • •Expected survival > 6 months

排除标准

  • •Active infection
  • •Metastatic disease
  • •Inadequate liver function after derivative surgery
  • •Inadequate renal function
  • •Pregnancy, breast feeding
  • •Use of any other investigational agent in the month before enrollment
  • •Patients with grade 2 or more neuropathy

结局指标

主要结局

Feasibility

Tolerance

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Feasibility of Radiotherapy and Concomitant... | 临床试验